Immunobody®
ImmunoBody® DNA active immunotherapies encode a protein in the form of a modified antibody, which is engineered to express epitopes from a cancer antigen whilst retaining the ability to target activated antigen presenting cells in vivo.
iSCIB1+ is Scancell’s lead ImmunoBody®
iSCIB1+ encodes a protein in the form of a modified antibody, which is engineered to express gp100 and TRP-2 epitopes whilst retaining the ability to target activated antigen presenting cells in vivo. By doing so, iSCIB1+ activates high-avidity T cells to generate a potent, lasting immune response, setting a new benchmark in the treatment of advanced metastatic melanoma. Around 80% of advanced melanoma patients have target HLA haplotypes.
iSCIB1+ and its earlier version SCIB1, with around half the melanoma-specific epitopes, have both demonstrated durable potent anti-tumour responses in combination with checkpoint inhibitors (CPIs) in our Phase 2 SCOPE trial. SCIB1 has also demonstrated efficacy as a monotherapy in patients with adjuvant melanoma.
Supported by a robust GMP manufacturing process and a stable shelf life, iSCIB1+ offers a fast route to treatment for patients.
To learn more about the mechanism hover over the numbers within the diagram above.
Targets antigen presenting cells in vivo to give potent T cell responses, attacking cancer on multiple fronts.
Phase 3 ready for registrational trial with clear path to commercialisation
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.